Clinical Overview
Sunitinib Capsules (12.5mg, 25mg) is an oral multi-targeted receptor tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It blocks signaling by VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, c-KIT, FLT3, and RET, exerting powerful anti-angiogenic and direct antiproliferative effects. Indicated for advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib, and progressive neuroendocrine tumors of pancreatic origin (pNET).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
RCC and GIST: Take orally 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (4/2 schedule) with or without food. pNET: Take 37.5 mg once daily continuously. Swallow capsules whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Fatigue/asthenia, diarrhea, hypertension, nausea, hand-foot syndrome, stomatitis, yellowish skin discoloration and hair depigmentation, hypothyroidism. Rare/Severe: Severe hepatotoxicity / liver failure, left ventricular dysfunction / congestive heart failure, osteonecrosis of the jaw (ONJ), and thrombotic microangiopathy.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Severe, potentially fatal hepatotoxicity; monitor liver enzymes at baseline, during each cycle, and as clinically indicated. Monitor blood pressure, thyroid function (TSH), and left ventricular ejection fraction regularly. Routine dental exam recommended prior to therapy to reduce osteonecrosis of the jaw risk.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.